<DOC>
	<DOCNO>NCT01815684</DOCNO>
	<brief_summary>The purpose study explore safety ( include effect cardiac interval ) , tolerability , effect Central Nervous System ( CNS ) , well CNS side effect profile single ascending dos ASP3652 healthy , Caucasian male female subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Effects Single Ascending Doses ASP3652 Healthy Subjects</brief_title>
	<detailed_description>Each subject receive 3 single ascend dos ASP3652 single dose match placebo one randomly select investigational period . Randomization conduct separately males female . The washout period dose occasion least 7 day . Screening take place Day -22 Day -2 . Subjects admit clinic afternoon Day -1 investigational period 1 , 2 , 3 4 pre-dose assessment . On Day -1 investigational period , subject take food drink least 10 hour anticipate dosing time Day 1 . For duration stay clinic , subject allow consume caffeine xanthine-containing drink . The subject discharge Day 4 investigational period . The End Study Visit ( ESV ) plan take place 7-14 day early discharge Day 4 investigational period 4 .</detailed_description>
	<criteria>Subject white Caucasian origin . Body Mass Index equal 18.5 less 30.0kg/m2 . Male subject must agree practice adequate contraceptive method female sexual partner prevent pregnancy . Female subject must agree practice adequate contraceptive method male sexual partner prevent pregnancy . Pregnancy within 6 month screen assessment breast feeding within 3 month screen ( female subject ) . Known suspected hypersensitivity ASP3652 , component formulation use . A mean QTc ( F ) interval &gt; 430 m ( male ) &gt; 450 m ( female ) triplicate measurement , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) . In case abnormal QTc ( F ) interval , assessment may repeat ( triplicate ) . If QTc ( F ) interval exceed limit , two additional Electrocardiogram ( ECG ) record average three QTc ( F ) value use determine subject 's eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>ASP3652</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Maximum Tolerated Dose ( MTD )</keyword>
</DOC>